This is of interest: https://colorectalcancer.org/article/alliance...ical-trial
Sounds a little like the I-SPY program, but for CRC. Inviting candidates, especially innovative combinational therapy.
"The study is designed as an adaptive trial platform, which will enable the simultaneous evaluation of multiple therapies under a single, overarching trial protocol."
We might have to be farther along in the CLOVER trial, with the ctDNA data translating to ORR, to be considered. But Dr. Kasi should be of help to get Leronlimab into this program. Hope Dr. Jay and Dr. Kasi are meeting with the Alliance in the Chicago ASCO meetings.
Sounds a little like the I-SPY program, but for CRC. Inviting candidates, especially innovative combinational therapy.
Quote:Alliance and GCAR Announce Collaboration to Advance a Groundbreaking Adaptive Clinical Trial Platform for CRC: KLEOS
"The study is designed as an adaptive trial platform, which will enable the simultaneous evaluation of multiple therapies under a single, overarching trial protocol."
Quote:For drug developers, the platform offers a more efficient and cost-effective pathway to evaluate assets, supporting faster, data-driven decision-making. By leveraging shared infrastructure and continuous learning, this model has the potential to generate high-quality clinical evidence more rapidly than traditional approaches, ultimately helping bring effective new therapies to patients sooner.
Quote:Pharmaceutical and biotechnology partners are invited to connect with GCAR and the Colorectal Cancer Alliance at the American Society of Clinical Oncology Annual Meeting (May 29 – June 2, Chicago) to learn more about KLEOS and explore opportunities to evaluate investigational assets within this innovative study framework.
We might have to be farther along in the CLOVER trial, with the ctDNA data translating to ORR, to be considered. But Dr. Kasi should be of help to get Leronlimab into this program. Hope Dr. Jay and Dr. Kasi are meeting with the Alliance in the Chicago ASCO meetings.
18
